泰利妥昔单抗联合B细胞清除疗法治疗MuSK抗体阳性重症肌无力：一例病例报告及文献综述
Telitacicept in combination with B-cell depletion therapy in MuSK antibody-positive myasthenia gravis: a case report and literature review.
作者信息
Wang Jia, Zheng Haotao, Wei Jia, Wu Jiaping, Feng Ziyang, Chen Xueqin, Liu Yangsicheng, Qin Wenxin, Qin Xiude, Kong Fanxin
机构信息
The Fourth Clinical Medical College, Guangzhou University of Chinese Medicine, Shenzhen, China.
Encephalopathy and Psychology Department, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China.
出版信息
Front Immunol. 2024 Nov 18;15:1456822. doi: 10.3389/fimmu.2024.1456822. eCollection 2024.
Muscle-specific kinase (MuSK) myasthenia gravis (MG) is relatively rare and has a higher incidence of myasthenic crisis compared with other subtypes. However, there is still a lack of effective treatment for refractory MuSK MG. We report the case of a 70-year-old female MuSK MG patient with recurrent fluctuations who stabilized on telitacicept in combination with anti-CD20 B-cell depletion therapy. This combination regimen deserves further investigation. Furthermore, we summarized the treatment protocols of 14 previously reported cases of MuSK MG.
肌肉特异性激酶（MuSK）重症肌无力（MG）相对罕见，与其他亚型相比，肌无力危象的发生率更高。然而，对于难治性MuSK MG仍缺乏有效的治疗方法。我们报告了一例70岁复发性波动的女性MuSK MG患者，在接受替利西普联合抗CD20 B细胞清除疗法后病情稳定。这种联合治疗方案值得进一步研究。此外，我们总结了14例先前报道的MuSK MG病例的治疗方案。
Zotero 插件